Nanoparticle flu vaccine shows promise at protecting mice
Using nanoparticle liposomes, researchers have developed an experimental flu vaccine that has shown success in pre-clinical studies.
“The results are very encouraging,” said the study’s senior author, Dr Jonathan Lovell. “Typically, flu vaccines contain either deactivated microbes that cause influenza or they are based on weakened forms of the disease. The vaccine we are developing is a recombinant protein nanoparticle vaccine that stimulates a strong immune response.”
Key to the vaccine’s success is a liposome the researchers created called cobalt-porphyrin-phospholipid (CoPoP). These tiny spherical sacs, small enough to be considered nanoparticles, form the backbone of the vaccine platform.
Alone, these liposomes do not fight disease, but they can spontaneously convert virus proteins that prompt immune responses into a more potent nanoparticle format.
“This conversion is advantageous because the dissolved proteins attach to the surface of the liposomes, where the proteins enhance the immune system’s response to disease,” said senior author Dr Matthew Miller, from McMaster University, Canada.
In the study, the researchers introduced a group of proteins known as haemagglutinin to the CoPop liposomes. They found that one particular haemagglutinin, known as trimeric H3 HA, triggered a strong immune response in mice.
“The nanoparticles carry the trimeric H3 HA to the body’s immune cells and they provoke those immune cells to respond more vigorously to the flu,” said lead author Dr Zachary Sia.
In experiments involving flu virus strain H3N2, blood serum from vaccinated mice was injected into non-vaccinated mice. The injection provided protection against H3N2. In experiments with ferrets involving a more modern H3N2 strain, the vaccine reduced the amount of virus in the animals’ upper respiratory system.
Even with doses as low as two nanograms, the vaccine provided a similar level of protection that vaccines with doses typically measured in micrograms, or roughly 1,000 times more.
“The dose-sparing effect is important because it means we could create many more doses using less materials,” explained senior co-author Dr Bruce Davidson. “Simply put, CoPoP likely will provide greater immune protection with less haemagglutinin than current vaccines.”
The team were also able to simultaneously bind 10 recombinant proteins representing distinct influenza virus strains to generate a highly multivalent nanoparticle. A five nanogram dose in mice offered protection against the H5N1 flu strain, more commonly known as bird flu.
The results of the study are published in the Proceedings of the National Academy of Sciences.